Groowe Groowe / Newsroom / SYRE
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

SYRE News

Spyre Therapeutics, Inc. Common Stock

Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach

globenewswire.com
SYRE

Spyre Therapeutics Announces Grants of Inducement Awards

globenewswire.com
SYRE

Spyre Therapeutics Announces Grants of Inducement Awards

globenewswire.com
SYRE

Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

globenewswire.com
SYRE

Spyre Therapeutics Announces Grants of Inducement Awards

globenewswire.com
SYRE

Spyre Therapeutics Announces Grants of Inducement Awards

globenewswire.com
SYRE

Spyre Therapeutics Announces Grants of Inducement Awards

globenewswire.com
SYRE

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

globenewswire.com
SYRE

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

globenewswire.com
SYRE

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

globenewswire.com
SYRE